nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ALB—focal segmental glomerulosclerosis	0.296	1	CbGaD
Vandetanib—ABCC1—Cyclosporine—focal segmental glomerulosclerosis	0.126	0.551	CbGbCtD
Vandetanib—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.0844	0.369	CbGbCtD
Vandetanib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0182	0.0797	CbGbCtD
Vandetanib—Posterior reversible encephalopathy syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00914	0.0874	CcSEcCtD
Vandetanib—FLT4—endothelium—focal segmental glomerulosclerosis	0.00654	0.0623	CbGeAlD
Vandetanib—RIPK2—endothelium—focal segmental glomerulosclerosis	0.0065	0.062	CbGeAlD
Vandetanib—TEK—endothelium—focal segmental glomerulosclerosis	0.00526	0.0501	CbGeAlD
Vandetanib—SRC—endothelium—focal segmental glomerulosclerosis	0.00467	0.0445	CbGeAlD
Vandetanib—KDR—endothelium—focal segmental glomerulosclerosis	0.0043	0.041	CbGeAlD
Vandetanib—Pyelonephritis—Cyclosporine—focal segmental glomerulosclerosis	0.00395	0.0377	CcSEcCtD
Vandetanib—Altered state of consciousness—Cyclosporine—focal segmental glomerulosclerosis	0.00325	0.0311	CcSEcCtD
Vandetanib—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00315	0.0301	CcSEcCtD
Vandetanib—RIPK2—nephron tubule—focal segmental glomerulosclerosis	0.00298	0.0284	CbGeAlD
Vandetanib—VEGFA—nephron tubule—focal segmental glomerulosclerosis	0.00297	0.0283	CbGeAlD
Vandetanib—FMO1—nephron tubule—focal segmental glomerulosclerosis	0.00295	0.0282	CbGeAlD
Vandetanib—ERBB3—nephron tubule—focal segmental glomerulosclerosis	0.00285	0.0272	CbGeAlD
Vandetanib—Micturition urgency—Cyclosporine—focal segmental glomerulosclerosis	0.00264	0.0253	CcSEcCtD
Vandetanib—FMO1—kidney—focal segmental glomerulosclerosis	0.0026	0.0248	CbGeAlD
Vandetanib—FLT4—cortex of kidney—focal segmental glomerulosclerosis	0.00256	0.0244	CbGeAlD
Vandetanib—VEGFA—cortex of kidney—focal segmental glomerulosclerosis	0.00254	0.0242	CbGeAlD
Vandetanib—SLK—nephron tubule—focal segmental glomerulosclerosis	0.00253	0.0242	CbGeAlD
Vandetanib—FMO1—cortex of kidney—focal segmental glomerulosclerosis	0.00253	0.0241	CbGeAlD
Vandetanib—ERBB3—kidney—focal segmental glomerulosclerosis	0.00251	0.0239	CbGeAlD
Vandetanib—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.00247	0.0236	CcSEcCtD
Vandetanib—FYN—nephron tubule—focal segmental glomerulosclerosis	0.00246	0.0235	CbGeAlD
Vandetanib—Serum creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00244	0.0233	CcSEcCtD
Vandetanib—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.00239	0.0228	CcSEcCtD
Vandetanib—Hypomagnesaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00236	0.0226	CcSEcCtD
Vandetanib—RET—kidney—focal segmental glomerulosclerosis	0.00232	0.0222	CbGeAlD
Vandetanib—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00231	0.0221	CcSEcCtD
Vandetanib—MKNK1—cortex of kidney—focal segmental glomerulosclerosis	0.00229	0.0218	CbGeAlD
Vandetanib—AXL—cortex of kidney—focal segmental glomerulosclerosis	0.00225	0.0215	CbGeAlD
Vandetanib—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.00224	0.0215	CcSEcCtD
Vandetanib—YES1—nephron tubule—focal segmental glomerulosclerosis	0.00222	0.0212	CbGeAlD
Vandetanib—SLK—cortex of kidney—focal segmental glomerulosclerosis	0.00217	0.0207	CbGeAlD
Vandetanib—FYN—kidney—focal segmental glomerulosclerosis	0.00217	0.0206	CbGeAlD
Vandetanib—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.00212	0.0203	CcSEcCtD
Vandetanib—TEK—kidney—focal segmental glomerulosclerosis	0.00212	0.0202	CbGeAlD
Vandetanib—FYN—cortex of kidney—focal segmental glomerulosclerosis	0.00211	0.0201	CbGeAlD
Vandetanib—TEK—cortex of kidney—focal segmental glomerulosclerosis	0.00206	0.0197	CbGeAlD
Vandetanib—MAP4K5—cortex of kidney—focal segmental glomerulosclerosis	0.00206	0.0197	CbGeAlD
Vandetanib—EPHB6—cortex of kidney—focal segmental glomerulosclerosis	0.00197	0.0188	CbGeAlD
Vandetanib—KDR—nephron tubule—focal segmental glomerulosclerosis	0.00197	0.0188	CbGeAlD
Vandetanib—YES1—kidney—focal segmental glomerulosclerosis	0.00195	0.0186	CbGeAlD
Vandetanib—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.00194	0.0186	CcSEcCtD
Vandetanib—STK10—kidney—focal segmental glomerulosclerosis	0.00194	0.0185	CbGeAlD
Vandetanib—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00193	0.0184	CcSEcCtD
Vandetanib—YES1—cortex of kidney—focal segmental glomerulosclerosis	0.0019	0.0181	CbGeAlD
Vandetanib—SRC—kidney—focal segmental glomerulosclerosis	0.00188	0.0179	CbGeAlD
Vandetanib—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.017	CcSEcCtD
Vandetanib—KDR—kidney—focal segmental glomerulosclerosis	0.00173	0.0165	CbGeAlD
Vandetanib—MAP2K5—cortex of kidney—focal segmental glomerulosclerosis	0.00168	0.0161	CbGeAlD
Vandetanib—KDR—cortex of kidney—focal segmental glomerulosclerosis	0.00168	0.0161	CbGeAlD
Vandetanib—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00165	0.0158	CcSEcCtD
Vandetanib—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.00158	0.0151	CcSEcCtD
Vandetanib—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00158	0.0151	CcSEcCtD
Vandetanib—ABL1—nephron tubule—focal segmental glomerulosclerosis	0.00152	0.0145	CbGeAlD
Vandetanib—PDGFRB—kidney—focal segmental glomerulosclerosis	0.0015	0.0143	CbGeAlD
Vandetanib—PDGFRB—cortex of kidney—focal segmental glomerulosclerosis	0.00146	0.0139	CbGeAlD
Vandetanib—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00136	0.013	CcSEcCtD
Vandetanib—ABL1—kidney—focal segmental glomerulosclerosis	0.00133	0.0127	CbGeAlD
Vandetanib—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.0124	CcSEcCtD
Vandetanib—ABL1—cortex of kidney—focal segmental glomerulosclerosis	0.0013	0.0124	CbGeAlD
Vandetanib—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.0117	CcSEcCtD
Vandetanib—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.0109	CcSEcCtD
Vandetanib—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.0107	CcSEcCtD
Vandetanib—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.0107	CcSEcCtD
Vandetanib—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.0106	CcSEcCtD
Vandetanib—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.00975	CcSEcCtD
Vandetanib—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.000998	0.00954	CcSEcCtD
Vandetanib—ABCC1—cortex of kidney—focal segmental glomerulosclerosis	0.00099	0.00944	CbGeAlD
Vandetanib—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.000964	0.00922	CcSEcCtD
Vandetanib—ABCG2—nephron tubule—focal segmental glomerulosclerosis	0.000958	0.00913	CbGeAlD
Vandetanib—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.000941	0.009	CcSEcCtD
Vandetanib—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.000926	0.00885	CcSEcCtD
Vandetanib—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000923	0.00882	CcSEcCtD
Vandetanib—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.000905	0.00865	CcSEcCtD
Vandetanib—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.00088	0.00842	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000875	0.00836	CcSEcCtD
Vandetanib—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.000869	0.00831	CcSEcCtD
Vandetanib—Erlotinib—ALB—focal segmental glomerulosclerosis	0.00086	0.615	CrCbGaD
Vandetanib—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000852	0.00814	CcSEcCtD
Vandetanib—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000849	0.00812	CcSEcCtD
Vandetanib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000844	0.00807	CcSEcCtD
Vandetanib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000839	0.00802	CcSEcCtD
Vandetanib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000839	0.00802	CcSEcCtD
Vandetanib—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.000837	0.008	CcSEcCtD
Vandetanib—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000825	0.00789	CcSEcCtD
Vandetanib—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000818	0.00782	CcSEcCtD
Vandetanib—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000816	0.0078	CcSEcCtD
Vandetanib—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000816	0.0078	CcSEcCtD
Vandetanib—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.0008	0.00765	CcSEcCtD
Vandetanib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.000794	0.00759	CcSEcCtD
Vandetanib—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000792	0.00757	CcSEcCtD
Vandetanib—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.000787	0.00753	CcSEcCtD
Vandetanib—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000757	0.00724	CcSEcCtD
Vandetanib—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000753	0.0072	CcSEcCtD
Vandetanib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000744	0.00711	CcSEcCtD
Vandetanib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000738	0.00706	CcSEcCtD
Vandetanib—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000726	0.00694	CcSEcCtD
Vandetanib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000684	0.00654	CcSEcCtD
Vandetanib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000679	0.00649	CcSEcCtD
Vandetanib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000673	0.00643	CcSEcCtD
Vandetanib—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000666	0.00637	CcSEcCtD
Vandetanib—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00066	0.00631	CcSEcCtD
Vandetanib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000656	0.00627	CcSEcCtD
Vandetanib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000642	0.00614	CcSEcCtD
Vandetanib—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000631	0.00603	CcSEcCtD
Vandetanib—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000618	0.00591	CcSEcCtD
Vandetanib—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000614	0.00587	CcSEcCtD
Vandetanib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000586	0.00559	CbGeAlD
Vandetanib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000572	0.00547	CcSEcCtD
Vandetanib—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000568	0.00543	CcSEcCtD
Vandetanib—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000566	0.00541	CcSEcCtD
Vandetanib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000558	0.00534	CcSEcCtD
Vandetanib—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000558	0.00534	CcSEcCtD
Vandetanib—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000556	0.00532	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000554	0.0053	CcSEcCtD
Vandetanib—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000546	0.00522	CcSEcCtD
Vandetanib—Gefitinib—ALB—focal segmental glomerulosclerosis	0.000538	0.385	CrCbGaD
Vandetanib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000535	0.00512	CcSEcCtD
Vandetanib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000532	0.00508	CcSEcCtD
Vandetanib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000525	0.00502	CcSEcCtD
Vandetanib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000524	0.00501	CcSEcCtD
Vandetanib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00052	0.00497	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000488	0.00466	CcSEcCtD
Vandetanib—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000484	0.00463	CcSEcCtD
Vandetanib—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000481	0.0046	CcSEcCtD
Vandetanib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000477	0.00456	CcSEcCtD
Vandetanib—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000471	0.0045	CcSEcCtD
Vandetanib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000465	0.00445	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000462	0.00442	CcSEcCtD
Vandetanib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000461	0.00441	CcSEcCtD
Vandetanib—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000458	0.00438	CcSEcCtD
Vandetanib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000458	0.00438	CcSEcCtD
Vandetanib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000438	0.00418	CcSEcCtD
Vandetanib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000423	0.00405	CcSEcCtD
Vandetanib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000423	0.00405	CcSEcCtD
Vandetanib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000384	0.00367	CcSEcCtD
Vandetanib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000379	0.00362	CcSEcCtD
Vandetanib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000366	0.0035	CcSEcCtD
Vandetanib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000354	0.00338	CcSEcCtD
Vandetanib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00034	0.00325	CcSEcCtD
Vandetanib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000337	0.00323	CcSEcCtD
Vandetanib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000337	0.00322	CcSEcCtD
Vandetanib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000335	0.00321	CcSEcCtD
Vandetanib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000318	0.00304	CcSEcCtD
Vandetanib—FYN—Hemostasis—ALB—focal segmental glomerulosclerosis	2.42e-05	9.17e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD79A—focal segmental glomerulosclerosis	2.42e-05	9.16e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.41e-05	9.13e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—NOS2—focal segmental glomerulosclerosis	2.4e-05	9.09e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	2.4e-05	9.07e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.39e-05	9.03e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.38e-05	9.02e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.36e-05	8.94e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	2.36e-05	8.93e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.34e-05	8.88e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	2.34e-05	8.87e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.34e-05	8.85e-05	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—MMP9—focal segmental glomerulosclerosis	2.29e-05	8.69e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.27e-05	8.59e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.27e-05	8.58e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.25e-05	8.53e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—LIPC—focal segmental glomerulosclerosis	2.25e-05	8.51e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	2.22e-05	8.42e-05	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.2e-05	8.34e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.2e-05	8.34e-05	CbGpPWpGaD
Vandetanib—SRC—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	2.19e-05	8.3e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—MMP2—focal segmental glomerulosclerosis	2.18e-05	8.25e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.18e-05	8.25e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—NOS2—focal segmental glomerulosclerosis	2.17e-05	8.2e-05	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.16e-05	8.18e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.15e-05	8.16e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—FN1—focal segmental glomerulosclerosis	2.15e-05	8.14e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.14e-05	8.12e-05	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.13e-05	8.06e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—NOS2—focal segmental glomerulosclerosis	2.12e-05	8.04e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD79A—focal segmental glomerulosclerosis	2.09e-05	7.91e-05	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.09e-05	7.9e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.09e-05	7.9e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.08e-05	7.86e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.07e-05	7.84e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.06e-05	7.81e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.05e-05	7.77e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD40LG—focal segmental glomerulosclerosis	2.05e-05	7.74e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.02e-05	7.66e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.02e-05	7.65e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	2.02e-05	7.65e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.02e-05	7.65e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—ALB—focal segmental glomerulosclerosis	2.02e-05	7.64e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.01e-05	7.63e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD79A—focal segmental glomerulosclerosis	2.01e-05	7.62e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.01e-05	7.61e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD40LG—focal segmental glomerulosclerosis	2e-05	7.58e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2e-05	7.58e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	1.99e-05	7.55e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD40LG—focal segmental glomerulosclerosis	1.99e-05	7.55e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.99e-05	7.54e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.99e-05	7.53e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.98e-05	7.49e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.98e-05	7.49e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	1.98e-05	7.49e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD40LG—focal segmental glomerulosclerosis	1.97e-05	7.46e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.96e-05	7.43e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.96e-05	7.43e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—MMP9—focal segmental glomerulosclerosis	1.96e-05	7.41e-05	CbGpPWpGaD
Vandetanib—MKNK1—Disease—TGFB1—focal segmental glomerulosclerosis	1.94e-05	7.36e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.94e-05	7.35e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—ALB—focal segmental glomerulosclerosis	1.94e-05	7.34e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—MMP9—focal segmental glomerulosclerosis	1.92e-05	7.29e-05	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.92e-05	7.28e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	1.92e-05	7.25e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.91e-05	7.22e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—MMP9—focal segmental glomerulosclerosis	1.9e-05	7.18e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	1.89e-05	7.14e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.88e-05	7.13e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.86e-05	7.04e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MMP2—focal segmental glomerulosclerosis	1.86e-05	7.04e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—LPL—focal segmental glomerulosclerosis	1.85e-05	7.02e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.84e-05	6.96e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—SERPINE1—focal segmental glomerulosclerosis	1.82e-05	6.9e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.82e-05	6.9e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.82e-05	6.88e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.8e-05	6.8e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	1.79e-05	6.77e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—LPL—focal segmental glomerulosclerosis	1.79e-05	6.76e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—ALB—focal segmental glomerulosclerosis	1.79e-05	6.76e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD79A—focal segmental glomerulosclerosis	1.78e-05	6.75e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.76e-05	6.68e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.76e-05	6.65e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	1.74e-05	6.59e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.74e-05	6.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.73e-05	6.53e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.72e-05	6.52e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.72e-05	6.51e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.71e-05	6.47e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.7e-05	6.45e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD40LG—focal segmental glomerulosclerosis	1.7e-05	6.45e-05	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.69e-05	6.4e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.69e-05	6.4e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.68e-05	6.36e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.67e-05	6.33e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.67e-05	6.33e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.66e-05	6.3e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.66e-05	6.29e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.66e-05	6.27e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.65e-05	6.25e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.65e-05	6.23e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.64e-05	6.22e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD40LG—focal segmental glomerulosclerosis	1.64e-05	6.21e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—LPL—focal segmental glomerulosclerosis	1.64e-05	6.2e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—MMP9—focal segmental glomerulosclerosis	1.64e-05	6.2e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.61e-05	6.11e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.6e-05	6.07e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.59e-05	6.03e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.59e-05	6.01e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.58e-05	5.98e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.58e-05	5.97e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	1.57e-05	5.93e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.56e-05	5.91e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.56e-05	5.89e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.55e-05	5.87e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.55e-05	5.87e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.54e-05	5.85e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—LPL—focal segmental glomerulosclerosis	1.54e-05	5.84e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.53e-05	5.81e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.53e-05	5.8e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.52e-05	5.76e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.51e-05	5.71e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—LPL—focal segmental glomerulosclerosis	1.49e-05	5.63e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	1.48e-05	5.6e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.47e-05	5.55e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.46e-05	5.52e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.46e-05	5.52e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD40LG—focal segmental glomerulosclerosis	1.45e-05	5.5e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—FN1—focal segmental glomerulosclerosis	1.45e-05	5.5e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.45e-05	5.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NOS2—focal segmental glomerulosclerosis	1.45e-05	5.48e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.44e-05	5.44e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NOS2—focal segmental glomerulosclerosis	1.43e-05	5.43e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.43e-05	5.42e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MMP9—focal segmental glomerulosclerosis	1.4e-05	5.29e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—NOS2—focal segmental glomerulosclerosis	1.4e-05	5.28e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.39e-05	5.28e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.38e-05	5.24e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—LPL—focal segmental glomerulosclerosis	1.37e-05	5.19e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.36e-05	5.15e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.35e-05	5.11e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.35e-05	5.1e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.34e-05	5.06e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.32e-05	5.02e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—LPL—focal segmental glomerulosclerosis	1.32e-05	4.99e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.31e-05	4.97e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.31e-05	4.96e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.3e-05	4.91e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.29e-05	4.89e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.29e-05	4.88e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NOS2—focal segmental glomerulosclerosis	1.28e-05	4.84e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.28e-05	4.83e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.28e-05	4.83e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.27e-05	4.81e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.27e-05	4.79e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.25e-05	4.74e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.23e-05	4.65e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.23e-05	4.64e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—LIPC—focal segmental glomerulosclerosis	1.22e-05	4.62e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—SERPINE1—focal segmental glomerulosclerosis	1.22e-05	4.62e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	1.21e-05	4.57e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	1.21e-05	4.57e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NOS2—focal segmental glomerulosclerosis	1.21e-05	4.56e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.2e-05	4.56e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.18e-05	4.49e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—SERPINE1—focal segmental glomerulosclerosis	1.17e-05	4.45e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AGT—focal segmental glomerulosclerosis	1.17e-05	4.44e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NOS2—focal segmental glomerulosclerosis	1.16e-05	4.4e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.16e-05	4.39e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.15e-05	4.36e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—TGFB1—focal segmental glomerulosclerosis	1.15e-05	4.36e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.13e-05	4.28e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.12e-05	4.24e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.12e-05	4.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.11e-05	4.22e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.11e-05	4.2e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.11e-05	4.2e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.09e-05	4.12e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.08e-05	4.09e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—SERPINE1—focal segmental glomerulosclerosis	1.08e-05	4.08e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CTGF—focal segmental glomerulosclerosis	1.07e-05	4.07e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.07e-05	4.06e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.07e-05	4.05e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.04e-05	3.94e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	1.03e-05	3.91e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS2—focal segmental glomerulosclerosis	1.03e-05	3.89e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.03e-05	3.88e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.02e-05	3.88e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—SERPINE1—focal segmental glomerulosclerosis	1.02e-05	3.84e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.01e-05	3.84e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1e-05	3.8e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.9e-06	3.75e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.89e-06	3.74e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	9.89e-06	3.74e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	9.86e-06	3.74e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—SERPINE1—focal segmental glomerulosclerosis	9.78e-06	3.7e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.78e-06	3.7e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	9.5e-06	3.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AGT—focal segmental glomerulosclerosis	9.25e-06	3.5e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LPL—focal segmental glomerulosclerosis	9.22e-06	3.49e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.14e-06	3.46e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ALB—focal segmental glomerulosclerosis	9e-06	3.41e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AGT—focal segmental glomerulosclerosis	8.91e-06	3.37e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.89e-06	3.37e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	8.73e-06	3.31e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—SERPINE1—focal segmental glomerulosclerosis	8.66e-06	3.28e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.59e-06	3.25e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FN1—focal segmental glomerulosclerosis	8.54e-06	3.23e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	8.54e-06	3.23e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.36e-06	3.17e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	8.36e-06	3.16e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FN1—focal segmental glomerulosclerosis	8.23e-06	3.12e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	8.23e-06	3.12e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.15e-06	3.09e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.06e-06	3.05e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	7.92e-06	3e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGT—focal segmental glomerulosclerosis	7.89e-06	2.99e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TGFB1—focal segmental glomerulosclerosis	7.7e-06	2.91e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	7.63e-06	2.89e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—LPL—focal segmental glomerulosclerosis	7.45e-06	2.82e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TGFB1—focal segmental glomerulosclerosis	7.42e-06	2.81e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.33e-06	2.77e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FN1—focal segmental glomerulosclerosis	7.29e-06	2.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	7.11e-06	2.69e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.08e-06	2.68e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	6.85e-06	2.59e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—focal segmental glomerulosclerosis	6.8e-06	2.57e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	6.59e-06	2.49e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	6.54e-06	2.48e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—focal segmental glomerulosclerosis	6.41e-06	2.43e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	6.4e-06	2.42e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGT—focal segmental glomerulosclerosis	6.37e-06	2.41e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	6.3e-06	2.39e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—focal segmental glomerulosclerosis	6.18e-06	2.34e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	6.06e-06	2.3e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	5.8e-06	2.2e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—focal segmental glomerulosclerosis	5.47e-06	2.07e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.45e-06	2.06e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.39e-06	2.04e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.34e-06	2.02e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.28e-06	2e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.25e-06	1.99e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.19e-06	1.97e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.65e-06	1.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.49e-06	1.7e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.32e-06	1.64e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	4.02e-06	1.52e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.83e-06	1.45e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	3.44e-06	1.3e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	2.64e-06	9.99e-06	CbGpPWpGaD
